Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ALG-055009

Other · developed by Aligos Therapeutics

Phase 2 Most advanced trial (none active)
ALGS Developer
1 Registered trials

What is ALG-055009?

ALG-055009 is a drug studied in metabolic dysfunction-associated steatohepatitis (MASH), also called nonalcoholic steatohepatitis (NASH), a form of non-alcoholic fatty liver disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Gastroenterology
Developer
Aligos Therapeutics (ALGS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06342947 Phase 2 NASH Completed ALGS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

MASHMetabolic Dysfunction-Associated SteatohepatitisNASHNonalcoholic Steatohepatitis

More from Aligos Therapeutics

ALG-010133 Phase 1 ALG-020572 Phase 1 ALG-097558 Phase 1 ALG-125755 Phase 1 Pevifoscorvir Phase 2

Follow ALGS, the company behind ALG-055009

See ALGS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALGS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.